Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Oncodesign

company

About

Oncodesign develops anticancer therapies for the treatment of patients with cancer.

  • 101 - 250

Details

Last Funding Type
Series C
Last Funding Money Raised
$4.71M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1995
Number Of Employee
101 - 250
Operating Status
Active

Pharmacological expertise for anticancer therapies from target to patient : a unique oncology preclinical CRO.


Founded in 1995, Oncodesign is a biopharmaceutical company that fills in the innovation gaps in the healthcare industry, based on its unique precision medicine platform. Technological innovation lies at the heart of Oncodesign’s model—the Etiology, Discovery and Experimentation activities designed and implemented by Oncodesign contribute to a more effective approach to the phenomenon of innate and acquired resistance, more effective treatments and a reduction in therapeutic failures.

Working alongside big pharma, biotech’s, public research institutions and investment groups, Oncodesign orients the research and development of new therapeutic and diagnostic tools. Through its range of services, partnerships and licensing programs, Oncodesign’s offering can meet the full range of innovation needs.

Oncodesign is listed on the Euronext Growth Paris market and possesses a stable ownership structure with a majority owner committed to its development.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$4.71M
Oncodesign has raised a total of $4.71M in funding over 2 rounds. Their latest funding was raised on May 22, 2008 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 22, 2008 Series C $4.71M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Oncodesign is funded by 1 investors. Avenir Entreprises Gestion are the most recent investors.
Investor Name Lead Investor Funding Round
Avenir Entreprises Gestion Series C